Novo Nordisk CEO Lars Fruergaard Jørgensen weighs in the company's latest obesity drug offering, including its new oral ...

We recently compiled a list of the Jim Cramer Discussed These 11 Stocks Before The DeepSeek Sell-Off. In this article, we are ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Eli Lilly reported fourth quarter and full year earnings for 2024 Thursday, with results largely beating Wall Street ...

Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

BI Illustration Eli Lilly makes the popular shots Mounjaro and Zepbound. Next, the company says they have a pill coming that could be as powerful as rival Ozempic. The company's head of obesity said ...

Novo Nordisk's phase 1b/2a clinical trial results revealed that their investigational drug, amycretin, led to an average weight loss of 22% over 36 weeks. This is in contrast to a 2% increase observed ...

Besides its existing GLP-1 offerings, Eli Lilly may appeal to investors for its pill version of tirzepatide—likely on the horizon in 2026—as well as for its oncology products. Indeed ...